Plasma and cerebrospinal fluid interleukin-1β during lipopolysaccharide-induced systemic inflammation in ewes implanted or not with slow-release melatonin

Janina Skipor; Marta Kowalewska; Aleksandra Szczepkowska; Anna Majewska; Tomasz Misztal; Marek Jalynski; Andrzej P Herman; Katarzyna Zabek

doi:10.1186/s40104-017-0206-0

Plasma and cerebrospinal fluid interleukin-1β during lipopolysaccharide-induced systemic inflammation in ewes implanted or not with slow-release melatonin

J Anim Sci Biotechnol. 2017 Oct 1:8:76. doi: 10.1186/s40104-017-0206-0. eCollection 2017.

Authors

Janina Skipor¹, Marta Kowalewska¹, Aleksandra Szczepkowska¹, Anna Majewska¹, Tomasz Misztal², Marek Jalynski³, Andrzej P Herman², Katarzyna Zabek⁴

Affiliations

¹ Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, Poland.
² The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, Jablonna n/Warsaw, Olsztyn, Poland.
³ Veterinary Medicine Faculty, University of Warmia and Mazury, Olsztyn, Poland.
⁴ Department of Sheep and Goat Breeding, Animal Bioengineering Faculty, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.

Abstract

Background: Interleukin-1β (IL-1β) is important mediator of inflammatory-induced suppression of reproductive axis at the hypothalamic level. At the beginning of inflammation, the main source of cytokines in the cerebrospinal fluid (CSF) is peripheral circulation, while over time, cytokines produced in the brain are more important. Melatonin has been shown to decrease pro-inflammatory cytokines concentration in the brain. In ewes, melatonin is used to advance the onset of a breading season. Little is known about CSF concentration of IL-1β in ewes and its correlation with plasma during inflammation as well as melatonin action on the concentration of IL-1β in blood plasma and the CSF, and brain barriers permeability in early stage of lipopolysaccharide (LPS)-induced inflammation.

Methods: Systemic inflammation was induced through LPS administration in melatonin- and sham-implanted ewes. Blood and CSF samples were collected before and after LPS administration and IL-1β and albumin concentration were measured. To assess the functions of brain barriers albumin quotient (QAlb) was used. Expression of IL-1β (Il1B) and its receptor type I (Il1r1) and type II (Il1r2) and matrix metalloproteinase (Mmp) 3 and 9 was evaluated in the choroid plexus (CP).

Results: Before LPS administration, IL-1β was on the level of 62.0 ± 29.7 pg/mL and 66.4 ± 32.1 pg/mL in plasma and 26.2 ± 5.4 pg/mL and 21.3 ± 8.7 pg/mL in the CSF in sham- and melatonin-implanted group, respectively. Following LPS it increased to 159.3 ± 53.1 pg/mL and 197.8 ± 42.8 pg/mL in plasma and 129.8 ± 54.2 pg/mL and 139.6 ± 51.5 pg/mL in the CSF. No correlations was found between plasma and CSF IL-1β concentration after LPS in both groups. The QAlb calculated before LPS and 6 h after was similar in all groups. Melatonin did not affected mRNA expression of Il1B, Il1r1 and Il1r2 in the CP. The mRNA expression of Mmp3 and Mmp9 was not detected.

Conclusions: The lack of correlation between plasma and CSF IL-1β concentration indicates that at the beginning of inflammation the local synthesis of IL-1β in the CP is an important source of IL-1β in the CSF. Melatonin from slow-release implants does not affect IL-1β concentration in plasma and CSF in early stage of systemic inflammation.

Keywords: Albumin; Cerebrospinal fluid; Ewes; Interleukin −1β; LPS; Melatonin.